Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results

NextCure, Inc. (NXTC) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
07/19/2023 8-K Quarterly results
05/04/2023 8-K Quarterly results
03/02/2023 8-K Quarterly results
11/03/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
06/23/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
03/03/2022 8-K Quarterly results
11/15/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "NextCure and Collaborators Provide Clinical and Research Updates on NC318 and NC410 Candidates at Society for Immunotherapy of Cancer Annual Meeting BELTSVILLE, Md. – November 13, 2021 -- NextCure, Inc. , a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced new data from two clinical studies and one research study presented at the Society for Immunotherapy of Cancer annual meeting in Washington, D.C., and on a virtual platform. The data come from clinical studies evaluating NC318, a Siglec-15 antibody, and NC410, a fusion protein of LAIR-2, in patients with advanced/metastatic solid tumors, as well as from a research study evaluating NC410’ s impact on T ce...",
"Investor presentation issued by NextCure, Inc."
11/04/2021 8-K Quarterly results
Docs: "NEXTCURE, INC. CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Revenue: Revenue from former research and development arrangement $ — $ — $ — $ 22,378 Operating expenses: Research and development 13,597 12,740 37,928 34,448 General and administrative 4,911 4,659 15,766 12,918 Total operating expenses 18,508 17,399 53,694 47,366 Loss from operations Other income, net 578 1,032 1,244 3,846 Net loss $ $ $ $ Loss per share - basic and diluted $ $ $ $ Weighted-average shares outstanding - basic and diluted 27,615,038 27,547,737 27,607,685 27,524,350 Comprehensive loss: Net loss $ $ $ $ Unrealized gain on marketable securities 66 1,298 Total comprehensive loss $ $ $ $ NEXTCURE, INC. CONDENSED BALANCE..."
10/04/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "NextCure Announces New Appointments to its Board of Directors"
09/24/2021 8-K Quarterly results
08/05/2021 8-K Quarterly results
Docs: "NextCure Reports Second Quarter 2021 Financial Results"
06/25/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
03/04/2021 8-K Quarterly results
02/24/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/14/2021 8-K Quarterly results
09/14/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Non-Employee Director Compensation Program",
"NextCure Announces Appointment of John G. Houston, Ph.D., to its Board of Directors"
07/31/2020 8-K Quarterly results
07/17/2020 8-K Quarterly results
07/13/2020 8-K Quarterly results
06/11/2020 8-K Submission of Matters to a Vote of Security Holders
03/30/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "NextCure Announces Appointment of Veteran Oncology Executive Garry Nicholson to its Board of Directors"
01/13/2020 8-K Termination of a Material Definitive Agreement
12/02/2019 8-K Other Events
10/02/2019 8-K Quarterly results
08/08/2019 8-K Regulation FD Disclosure
05/13/2019 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
Docs: "Amended and Restated Certificate of Incorporation of NextCure, Inc",
"AMENDED AND RESTATED BYLAWS OF NEXTCURE, INC. ARTICLE I"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy